BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2018 8:56:32 AM | Browse: 816 | Download: 922
 |
Received |
|
2018-10-13 08:50 |
|
Peer-Review Started |
|
2018-10-14 04:48 |
|
To Make the First Decision |
|
2018-11-08 06:11 |
|
Return for Revision |
|
2018-11-14 08:00 |
|
Revised |
|
2018-12-11 12:09 |
|
Second Decision |
|
2018-12-19 09:56 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-12-21 05:24 |
|
Articles in Press |
|
2018-12-21 05:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-12-26 02:43 |
|
Publish the Manuscript Online |
|
2018-12-27 08:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sandra Wagner, Christina S Mullins and Michael Linnebacher |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministerium für Wirtschaft, Arbeit und Gesundheit Mecklenburg-Vorpommern |
TBI-V-1-241-VBW-084 |
|
| Corresponding Author |
Michael Linnebacher, PhD, Academic Fellow, Postdoc, Research Fellow, Research Scientist, Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, Schillingallee 35, Rostock 18055, Germany. michael.linnebacher@med.uni-rostock.de |
| Key Words |
Cancer vaccines; Colorectal neoplasm; Immunotherapy; Neoplasm antigen; tumor-associated antigens; tumor-specific antigens; Neoantigen(s) |
| Core Tip |
Peptide vaccines are a promising tool for colorectal cancer (CRC) treatment. Direct comparison of tumor-associated antigens (TAAs) and neoantigens reveals clear superiority of the latter for several reasons. TAAs, albeit easier to identify and even shared by many patients, did not prove effective in clinical trials. Additionally, and due to their unspecificity, they frequently trigger severe adverse events. This risk is neglectable for tumor-specific neoantigens - thus compensating for the costly and laborious identification of such antigens expressed in individual patient tumors. Intelligent modern CRC vaccines will likely combine several or even many individual neoantigen-derived peptides with immuno-chemotherapy, adjuvants or further immuno-modulators. |
| Publish Date |
2018-12-27 08:56 |
| Citation |
Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432 |
| URL |
https://www.wjgnet.com/1007-9327/full/v24/i48/5418.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v24.i48.5418 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
